DexCom, Inc. (DXCM)
NASDAQ: DXCM · Real-Time Price · USD
64.24
-1.02 (-1.56%)
At close: Mar 13, 2026, 4:00 PM EDT
64.58
+0.34 (0.53%)
After-hours: Mar 13, 2026, 7:59 PM EDT
DexCom Revenue
In the year 2025, DexCom had annual revenue of $4.66B with 15.60% growth. DexCom had revenue of $1.26B in the quarter ending December 31, 2025, with 13.12% growth.
Revenue (ttm)
$4.66B
Revenue Growth
+15.60%
P/S Ratio
5.30
Revenue / Employee
$420,000
Employees
11,100
Market Cap
24.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.66B | 629.00M | 15.60% |
| Dec 31, 2024 | 4.03B | 410.70M | 11.34% |
| Dec 31, 2023 | 3.62B | 712.50M | 24.49% |
| Dec 31, 2022 | 2.91B | 461.30M | 18.84% |
| Dec 31, 2021 | 2.45B | 521.80M | 27.08% |
| Dec 31, 2020 | 1.93B | 450.70M | 30.54% |
| Dec 31, 2019 | 1.48B | 444.40M | 43.08% |
| Dec 31, 2018 | 1.03B | 313.10M | 43.58% |
| Dec 31, 2017 | 718.50M | 145.20M | 25.33% |
| Dec 31, 2016 | 573.30M | 171.30M | 42.61% |
| Dec 31, 2015 | 402.00M | 142.80M | 55.09% |
| Dec 31, 2014 | 259.20M | 99.20M | 62.00% |
| Dec 31, 2013 | 160.00M | 60.10M | 60.16% |
| Dec 31, 2012 | 99.90M | 23.60M | 30.93% |
| Dec 31, 2011 | 76.30M | 27.70M | 57.00% |
| Dec 31, 2010 | 48.60M | 18.91M | 63.67% |
| Dec 31, 2009 | 29.69M | 19.86M | 201.82% |
| Dec 31, 2008 | 9.84M | 5.21M | 112.62% |
| Dec 31, 2007 | 4.63M | 2.46M | 113.23% |
| Dec 31, 2006 | 2.17M | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Koninklijke Philips | 20.94B |
| GE HealthCare Technologies | 20.63B |
| Zimmer Biomet Holdings | 8.23B |
| Smith & Nephew | 6.16B |
| Edwards Lifesciences | 6.07B |
| STERIS | 5.83B |
| Globus Medical | 2.94B |
| Insulet | 2.71B |
DXCM News
- 4 days ago - Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026 - Business Wire
- 11 days ago - DexCom: Gaining Favor, With Useful Tailwinds To Support It Even Further - Seeking Alpha
- 13 days ago - DexCom, Inc. (DXCM) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript - Seeking Alpha
- 17 days ago - Dexcom Appoints Rick Osterloh to Board of Directors - Business Wire
- 17 days ago - HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PRNewsWire
- 18 days ago - Dexcom Announces Upcoming Conference Presentation - Business Wire
- 4 weeks ago - DexCom, Inc. (DXCM) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - DexCom Reports Better-Than-Expected Q4 Results: Details - Benzinga